Severe Lenalidomide-Associated Hyperbilirubinemia

被引：1

作者：

Gildea, Daniel T. ^{[1
]}

Roswarski, Joseph L. ^{[2
]}

机构：

[1] MedStar Georgetown Univ Hosp, Internal Med, Washington, DC 20007 USA

[2] MedStar Georgetown Univ Hosp, Hematol & Oncol, Washington, DC USA

来源：

CUREUS JOURNAL OF MEDICAL SCIENCE | 2023年 / 15卷 / 01期

关键词：

oncology; treatment related toxicity; cholestatic liver injury; extra-medullary plasmacytoma; immunomodulatory imide drugs; direct hyperbilirubinemia; hepatology; MYELOMA;

D O I：

10.7759/cureus.34408

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Immunomodulatory drugs (IMids), such as thalidomide and lenalidomide, are used to treat plasma cell neoplasms and B-cell malignancies. We present a case of severe direct hyperbilirubinemia in a patient taking lenalidomide-based therapy for plasmacytoma. Imaging was unrevealing, and liver biopsy showed only mild sinusoidal dilation. Roussel Uclaf Causality Assessment (RUCAM) score was 6, indicating lenalidomide was a probable cause of the injury. To our knowledge, this is the highest reported direct bilirubin regarding lenalidomide drug-induced liver injury (DILI), with a peak bilirubin of 41mg/dL. While a clear pathophysiology was not identified, this case provides important considerations regarding lenalidomide safety.

引用

页数：3

共 50 条

[1] Lenalidomide-associated hypothyroidism
Menon, Smitha
Habermann, Thomas
Witzig, Thomas
LEUKEMIA & LYMPHOMA, 2007, 48 (12) : 2465 - 2467
[2] Lenalidomide-Associated ITP
Herold, Christina I.
Gasparetto, Cristina
Arepally, Gowthami M.
CASE REPORTS IN HEMATOLOGY, 2011, 2011
[3] Lenalidomide-associated hemolytic anemia
Lim, Ming Y.
Raval, Jay S.
Richards, Kristy L.
Zeidner, Joshua F.
Foster, Matthew C.
LEUKEMIA & LYMPHOMA, 2015, 56 (09) : 2717 - 2719
[4] Lenalidomide-associated progressive multifocal leukoencephalopathy
Brigo, Francesco
Pagani, Elisabetta
Tezzon, Frediano
Masi, Elisa
Nardone, Raffaele
LEUKEMIA & LYMPHOMA, 2017, 58 (10) : 2514 - 2515
[5] Lenalidomide-associated VTE despite thromboprophylaxis
Reactions Weekly, 2020, 1788 (1) : 6 - 6
[6] A Phase 2 Trial of Colesevelam for Lenalidomide-Associated Diarrhea
Hultcrantz, Malin
Hassoun, Hani
Korde, Neha
Mailankody, Sham
Shekarkhand, Tala
Burge, Miranda
Maclachlan, Kylee H.
Patel, Dhwani
Shah, Urvi A.
Chung, David J.
Scordo, Michael
Barnett, Kelly
Blaslov, Jenna
Salcedo, Meghan
Caple, Julia
Tran, Linh
Hamid, Selena
Lahoud, Oscar B.
Landau, Heather
Shah, Gunjan L.
Giralt, Sergio A.
Derkach, Andriy
Tan, Carlyn
Peer, Cody
Figg, William D., Sr.
Usmani, Saad
Landgren, Ola
Lesokhin, Alexander M.
BLOOD, 2022, 140 : 4454 - 4456
[7] Lenalidomide-Associated Hemophagocytic Lymphohistiocytosis With Plasma Cell Phagocytosis
Runge, Elliot
Kou, Chung-ting J.
Rendo, Matthew
Lynch, David
Fenderson, Joshua
CUREUS JOURNAL OF MEDICAL SCIENCE, 2021, 13 (04)
[8] Lenalidomide-Associated Thyroid-Related Eyelid Retraction
Slean, Geraldine R.
Silkiss, Rona Z.
OPHTHALMIC PLASTIC AND RECONSTRUCTIVE SURGERY, 2018, 34 (02): : E46 - E48
[9] LENALIDOMIDE-ASSOCIATED DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS
Shanbhag, Anusha
Hammond, Drayton
Chatterjee, Kshitij
Joshi, Manish
CRITICAL CARE MEDICINE, 2016, 44 (12)
[10] Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma
Palumbo, A.
Rajkumar, S. V.
Dimopoulos, M. A.
Richardson, P. G.
Miguel, J. San
Barlogie, B.
Harousseau, J.
Zonder, J. A.
Cavo, M.
Zangari, M.
Attal, M.
Belch, A.
Knop, S.
Joshua, D.
Sezer, O.
Ludwig, H.
Vesole, D.
Blade, J.
Kyle, R.
Westin, J.
Weber, D.
Bringhen, S.
Niesvizky, R.
Waage, A.
von Lilienfeld-Toal, M.
Lonial, S.
Morgan, G. J.
Orlowski, R. Z.
Shimizu, K.
Anderson, K. C.
Boccadoro, M.
Durie, B. G.
Sonneveld, P.
Hussein, M. A.
LEUKEMIA, 2008, 22 (02) : 414 - 423

← 1 2 3 4 5 →